Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KPTI

KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

$6.95-0.10 (-1.42%)
Market Closed

5/100

KPTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

KPTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.27

Target 3M

$5.93

Target 6M

$5.6

KPTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KPTI Price Action

Last 7 days

10.0%

Last 30 days

-5.3%

Last 90 days

16.6%

Trailing 12 Months

-32.1%

KPTI RSI Chart

KPTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KPTI Valuation

Market Cap

118.5B

Price/Earnings (Trailing)

-950.91

Price/Sales (Trailing)

831.43

EV/EBITDA

-1.1K

Price/Free Cashflow

-1.3K

KPTI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.27

Target 3M

$5.93

Target 6M

$5.6

KPTI Fundamentals

KPTI Revenue

Revenue (TTM)

142.5M

Rev. Growth (Yr)

13.57%

Rev. Growth (Qtr)

16.12%

KPTI Earnings

Earnings (TTM)

-124.6M

Earnings Growth (Yr)

-3.29%

Earnings Growth (Qtr)

11.07%

KPTI Profitability

EBT Margin

-87.43%

Return on Equity

46.28%

Return on Assets

-129.5%

Free Cashflow Yield

-0.08%

KPTI Investor Care

Shares Dilution (1Y)

203996.99%

Diluted EPS (TTM)

-13.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025142.1M137.3M142.5M0
2024140.5M145.7M148.4M145.2M
2023148.1M146.0M145.9M146.0M
2022234.2M251.3M249.8M157.1M
2021113.2M102.3M118.7M209.8M
202058.9M82.9M91.1M108.1M
201933.0M35.6M38.3M40.9M
201811.5M31.4M31.7M30.3M
2017222.0K166.0K118.0K1.6M
20160309.0K207.0K179.0K
20150208.0K262.0K266.0K
2014325.0K213.0K234.0K229.0K
2013833.0K433.0K399.0K387.0K
2012272.5K393.0K513.5K634.0K
2011000152.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Karyopharm Therapeutics Inc

KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
 CEO
 WEBSITEkaryopharm.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES385

Karyopharm Therapeutics Inc Frequently Asked Questions

KPTI is the stock ticker symbol of Karyopharm Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Karyopharm Therapeutics Inc is 118.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KPTI's fair value in chart for subscribers.

The fair value guage provides a quick view whether KPTI is over valued or under valued. Whether Karyopharm Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karyopharm Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPTI.

As of Wed Jan 28 2026, KPTI's PE ratio (Price to Earnings) is -950.91 and Price to Sales (PS) ratio is 831.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPTI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Karyopharm Therapeutics Inc has provided -0.229 (multiply by 100 for percentage) rate of return.